Announces its financial results for the three and 12 months ended December 31, 2025. All amounts are in thousands of United States dollars unless otherwise stated. Fiscal 2025 revenue was $55.5 million, Adjusted EBITDA was $19.6 million and cash from operations was $17.1 million, compared to $56.6 million, $16.6 million and $8 million, respectively. Q4 2025 revenue was $15.2 million, Adjusted EBITDA was $5.7 million and cash from operations was $6.5 million, compared to $15.5 million, $5.6 million and $3.2 million, respectively. HLS Therapeutics Inc. shares T.HLS are trading unchanged at $4.27.
Stocks in play: HLS Therapeutics Inc.
Baystreet - Contributor Content 
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
/Adobe%20Inc%20logo%20on%20computer-by%20DANIEL%20CONSTANTE%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_billboard-by%20Poetra_RH%20via%20Shutterstock.jpg)
